Solebury Trout
Trout Updates: Solebury Trout November Sell-Side Update
Solebury Trout

The month of November saw moderate analyst turnover, with Mara Goldstein leaving Cantor for Mizuho, as well as HC Wainwright and BTIG adding two analysts each. The highly anticipated Allogene Therapeutics IPO saw it’s initial wave of sell-side coverage, with three buy or equivalent ratings and a neutral rating. Solebury Trout client PhaseBio also saw initial coverage following it’s $46M IPO in mid-October with buy or equivalent ratings across the board. Two Leerink analysts, Marc Goodman and Mani Foroohar, initiated coverage of their universe, neuroscience and gene therapy companies, respectively. Additionally, long-time analyst Charles Duncan initiated coverage on a series of SMID-cap biotechnology stocks.

Report can be found here